Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

EBV-directed viral-specific T-lymphocyte therapy for the treatment of EBV-driven lymphoma in two patients with primary immunodeficiency and DNA repair defects.

Rubinstein JD, Burns K, Absalon M, Lutzko C, Leemhuis T, Chandra S, Hanley PJ, Keller MD, Davies SM, Nelson A, Grimley M.

Pediatr Blood Cancer. 2020 Mar;67(3):e28126. doi: 10.1002/pbc.28126. Epub 2019 Dec 18.

PMID:
31850668
2.

HIV-Specific T Cells Can Be Generated against Non-escaped T Cell Epitopes with a GMP-Compliant Manufacturing Platform.

Patel S, Hanajiri R, Grant M, Saunders D, Van Pelt S, Keller M, Hanley PJ, Simon G, Nixon DF, Hardy D, Jones RB, Bollard CM.

Mol Ther Methods Clin Dev. 2019 Oct 11;16:11-20. doi: 10.1016/j.omtm.2019.10.001. eCollection 2020 Mar 13.

3.

Driving the CAR to the Bone Marrow Transplant Program.

Dave H, Jerkins L, Hanley PJ, Bollard CM, Jacobsohn D.

Curr Hematol Malig Rep. 2019 Dec;14(6):561-569. doi: 10.1007/s11899-019-00544-6. Review.

PMID:
31643018
4.

Impact of Mesenchymal Stromal Cell Delivery through Cardiopulmonary Bypass on Postnatal Neurogenesis.

Maeda T, Sarkislali K, Leonetti C, Kapani N, Dhari Z, Al Haj I, Ulrey R, Hanley PJ, Jonas RA, Ishibashi N.

Ann Thorac Surg. 2019 Sep 26. pii: S0003-4975(19)31424-9. doi: 10.1016/j.athoracsur.2019.08.036. [Epub ahead of print]

PMID:
31563487
5.

Generation of Norovirus-Specific T-Cells from Human Donors with Extensive Cross-Reactivity to Variant Sequences: Implications for Immunotherapy.

Hanajiri R, Sani GM, Saunders D, Hanley PJ, Chopra A, Mallal SA, Sosnovtsev SV, Cohen JI, Green KY, Bollard CM, Keller MD.

J Infect Dis. 2019 Sep 28. pii: jiz491. doi: 10.1093/infdis/jiz491. [Epub ahead of print]

PMID:
31562500
6.

Medulloblastoma rendered susceptible to NK-cell attack by TGFβ neutralization.

Powell AB, Yadavilli S, Saunders D, Van Pelt S, Chorvinsky E, Burga RA, Albihani S, Hanley PJ, Xu Z, Pei Y, Yvon ES, Hwang EI, Bollard CM, Nazarian J, Cruz CRY.

J Transl Med. 2019 Sep 23;17(1):321. doi: 10.1186/s12967-019-2055-4.

7.

The pipeline of antiviral T-cell therapy: what's in the clinic and undergoing development.

Fatic A, Zhang N, Keller MD, Hanley PJ.

Transfusion. 2020 Jan;60(1):7-10. doi: 10.1111/trf.15501. Epub 2019 Aug 30. Review.

PMID:
31469438
8.

Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study.

Hont AB, Cruz CR, Ulrey R, O'Brien B, Stanojevic M, Datar A, Albihani S, Saunders D, Hanajiri R, Panchapakesan K, Darko S, Banerjee P, Fortiz MF, Hoq F, Lang H, Wang Y, Hanley PJ, Dome JS, Bollard CM, Meany HJ.

J Clin Oncol. 2019 Sep 10;37(26):2349-2359. doi: 10.1200/JCO.19.00177. Epub 2019 Jul 29.

9.

Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients.

Abraham AA, John TD, Keller MD, Cruz CRN, Salem B, Roesch L, Liu H, Hoq F, Grilley BJ, Gee AP, Dave H, Jacobsohn DA, Krance RA, Shpall EJ, Martinez CA, Hanley PJ, Bollard CM.

Blood Adv. 2019 Jul 23;3(14):2057-2068. doi: 10.1182/bloodadvances.2019000201. Erratum in: Blood Adv. 2019 Aug 27;3(16):2453.

10.

Generation of Zika virus-specific T cells from seropositive and virus-naïve donors for potential use as an autologous or "off-the-shelf" immunotherapeutic.

Hanajiri R, Sani GM, Hanley PJ, Silveira CG, Kallas EG, Keller MD, Bollard CM.

Cytotherapy. 2019 Aug;21(8):840-855. doi: 10.1016/j.jcyt.2019.06.008. Epub 2019 Jul 4.

PMID:
31279695
11.

T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy.

Keller MD, Darko S, Lang H, Ransier A, Lazarski CA, Wang Y, Hanley PJ, Davila BJ, Heimall JR, Ambinder RF, Barrett AJ, Rooney CM, Heslop HE, Douek DC, Bollard CM.

Br J Haematol. 2019 Oct;187(2):206-218. doi: 10.1111/bjh.16053. Epub 2019 Jun 20.

PMID:
31219185
12.

Fresh versus Frozen: Effects of Cryopreservation on CAR T Cells.

Hanley PJ.

Mol Ther. 2019 Jul 3;27(7):1213-1214. doi: 10.1016/j.ymthe.2019.06.001. Epub 2019 Jun 13. No abstract available.

PMID:
31202635
13.

Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer.

Patel S, Burga RA, Powell AB, Chorvinsky EA, Hoq N, McCormack SE, Van Pelt SN, Hanley PJ, Cruz CRY.

Front Oncol. 2019 Apr 10;9:196. doi: 10.3389/fonc.2019.00196. eCollection 2019. Review.

14.

Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency Disorders.

Patel S, Lang H, Sani G, Freeman AF, Leiding J, Hanley PJ, Cruz CR, Grant M, Wang Y, Oshrine B, Palmer C, Holland SM, Bollard CM, Keller MD.

Front Immunol. 2019 Mar 29;10:621. doi: 10.3389/fimmu.2019.00621. eCollection 2019.

15.

Critical testing and parameters for consideration when manufacturing and evaluating tumor-associated antigen-specific T cells.

Tanna JG, Ulrey R, Williams KM, Hanley PJ.

Cytotherapy. 2019 Mar;21(3):278-288. doi: 10.1016/j.jcyt.2019.02.004. Epub 2019 Mar 28.

PMID:
30929992
16.

Proposal for the International Society for Cell & Gene Therapy position statement on assays for the quality control and potency assessment of adoptive cellular immunotherapies.

Weil B, Hanley PJ, Lowdell M.

Cytotherapy. 2019 Mar;21(3):367-375. doi: 10.1016/j.jcyt.2019.02.001. Epub 2019 Mar 16.

PMID:
30890307
17.

Advancing cellular therapies towards standard of care: a focus on testing of cellular therapy products.

Hanley PJ, Lowdell M.

Cytotherapy. 2019 Mar;21(3):275-277. doi: 10.1016/j.jcyt.2019.02.003. Epub 2019 Mar 7. No abstract available.

PMID:
30853266
18.

A novel isoform of myosin 18A (Myo18Aγ) is an essential sarcomeric protein in mouse heart.

Horsthemke M, Nutter LMJ, Bachg AC, Skryabin BV, Honnert U, Zobel T, Bogdan S, Stoll M, Seidl MD, Müller FU, Ravens U, Unger A, Linke WA, van Gorp PRR, de Vries AAF, Bähler M, Hanley PJ.

J Biol Chem. 2019 May 3;294(18):7202-7218. doi: 10.1074/jbc.RA118.004560. Epub 2019 Feb 8.

19.

Phenotypic analysis of Myo10 knockout (Myo10tm2/tm2) mice lacking full-length (motorized) but not brain-specific headless myosin X.

Bachg AC, Horsthemke M, Skryabin BV, Klasen T, Nagelmann N, Faber C, Woodham E, Machesky LM, Bachg S, Stange R, Jeong HW, Adams RH, Bähler M, Hanley PJ.

Sci Rep. 2019 Jan 24;9(1):597. doi: 10.1038/s41598-018-37160-y.

20.

Time-lapse 3D Imaging of Phagocytosis by Mouse Macrophages.

Horsthemke M, Wilden J, Bachg AC, Hanley PJ.

J Vis Exp. 2018 Oct 19;(140). doi: 10.3791/57566.

PMID:
30394377
21.

Build a Bank: Off-the-Shelf Virus-Specific T Cells.

Hanley PJ.

Biol Blood Marrow Transplant. 2018 Dec;24(12):e9-e10. doi: 10.1016/j.bbmt.2018.10.010. Epub 2018 Oct 18. No abstract available.

22.

EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation.

McLaughlin LP, Rouce R, Gottschalk S, Torrano V, Carrum G, Wu MF, Hoq F, Grilley B, Marcogliese AM, Hanley PJ, Gee AP, Brenner MK, Rooney CM, Heslop HE, Bollard CM.

Blood. 2018 Nov 29;132(22):2351-2361. doi: 10.1182/blood-2018-07-863654. Epub 2018 Sep 27.

23.

HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals.

Sung JA, Patel S, Clohosey ML, Roesch L, Tripic T, Kuruc JD, Archin N, Hanley PJ, Cruz CR, Goonetilleke N, Eron JJ, Rooney CM, Gay CL, Bollard CM, Margolis DM.

Mol Ther. 2018 Oct 3;26(10):2496-2506. doi: 10.1016/j.ymthe.2018.08.015. Epub 2018 Sep 21.

24.

Antiviral T Cells for Adenovirus in the Pretransplant Period: A Bridge Therapy for Severe Combined Immunodeficiency.

Miller HK, Hanley PJ, Lang H, Lazarski CA, Chorvinsky EA, McCormack S, Roesch L, Albihani S, Dean M, Hoq F, Adams RH, Bollard CM, Keller MD.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1944-1946. doi: 10.1016/j.bbmt.2018.04.030. Epub 2018 May 9.

25.

Low density lipoprotein interferes with intracellular signaling of monocytes resulting in impaired chemotaxis and enhanced chemokinesis.

Tjaden K, Adam C, Godfrey R, Hanley PJ, Pardali E, Waltenberger J.

Int J Cardiol. 2018 Mar 15;255:160-165. doi: 10.1016/j.ijcard.2017.11.109.

PMID:
29425557
26.

Aminoquinoline Fluorescent Labels Obstruct Efficient Removal of N-Glycan Core α(1-6) Fucose by Bovine Kidney α-l-Fucosidase (BKF).

O'Flaherty R, Harbison AM, Hanley PJ, Taron CH, Fadda E, Rudd PM.

J Proteome Res. 2017 Nov 3;16(11):4237-4243. doi: 10.1021/acs.jproteome.7b00580.

PMID:
28953389
27.

Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy.

Fesnak AD, Hanley PJ, Levine BL.

Curr Hematol Malig Rep. 2017 Aug;12(4):335-343. doi: 10.1007/s11899-017-0395-9. Review.

28.

Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood.

Dave H, Luo M, Blaney JW, Patel S, Barese C, Cruz CR, Shpall EJ, Bollard CM, Hanley PJ.

Mol Ther Methods Clin Dev. 2017 Mar 8;5:13-21. doi: 10.1016/j.omtm.2017.02.001. eCollection 2017 Jun 16.

29.

Intravenous mesenchymal stromal cell therapy for inflammatory bowel disease: Lessons from the acute graft versus host disease experience.

Conklin LS, Hanley PJ, Galipeau J, Barrett J, Bollard CM.

Cytotherapy. 2017 Jun;19(6):655-667. doi: 10.1016/j.jcyt.2017.03.006. Epub 2017 Apr 19. Review.

PMID:
28433516
30.

Mobilizing Immune Cells With Exercise for Cancer Immunotherapy.

Simpson RJ, Bigley AB, Agha N, Hanley PJ, Bollard CM.

Exerc Sport Sci Rev. 2017 Jul;45(3):163-172. doi: 10.1249/JES.0000000000000114. Review.

31.

Multiple roles of filopodial dynamics in particle capture and phagocytosis and phenotypes of Cdc42 and Myo10 deletion.

Horsthemke M, Bachg AC, Groll K, Moyzio S, Müther B, Hemkemeyer SA, Wedlich-Söldner R, Sixt M, Tacke S, Bähler M, Hanley PJ.

J Biol Chem. 2017 Apr 28;292(17):7258-7273. doi: 10.1074/jbc.M116.766923. Epub 2017 Mar 13.

32.

Mesenchymal stromal cell secretomes are modulated by suspension time, delivery vehicle, passage through catheter, and exposure to adjuvants.

Parsha K, Mir O, Satani N, Yang B, Guerrero W, Mei Z, Cai C, Chen PR, Gee A, Hanley PJ, Aronowski J, Savitz SI.

Cytotherapy. 2017 Jan;19(1):36-46. doi: 10.1016/j.jcyt.2016.10.006. Epub 2016 Nov 14.

PMID:
27856228
33.

Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes.

McLaughlin LP, Lang H, Williams E, Wright KE, Powell A, Cruz CR, Colberg-Poley AM, Barese C, Hanley PJ, Bollard CM, Keller MD.

Cytotherapy. 2016 Dec;18(12):1515-1524. doi: 10.1016/j.jcyt.2016.08.010. Epub 2016 Sep 28.

34.

Isolation and Manufacture of Clinical-Grade Bone Marrow-Derived Human Mesenchymal Stromal Cells.

Miller RP, Hanley PJ.

Methods Mol Biol. 2016;1416:301-12. doi: 10.1007/978-1-4939-3584-0_18.

PMID:
27236680
35.
36.

Real-time two- and three-dimensional imaging of monocyte motility and navigation on planar surfaces and in collagen matrices: roles of Rho.

Bzymek R, Horsthemke M, Isfort K, Mohr S, Tjaden K, Müller-Tidow C, Thomann M, Schwerdtle T, Bähler M, Schwab A, Hanley PJ.

Sci Rep. 2016 Apr 28;6:25016. doi: 10.1038/srep25016.

37.

Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.

Barth MJ, Chu Y, Hanley PJ, Cairo MS.

Br J Haematol. 2016 May;173(4):597-616. doi: 10.1111/bjh.14078. Epub 2016 Apr 7. Review.

PMID:
27062282
38.

Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes.

Naik S, Nicholas SK, Martinez CA, Leen AM, Hanley PJ, Gottschalk SM, Rooney CM, Hanson IC, Krance RA, Shpall EJ, Cruz CR, Amrolia P, Lucchini G, Bunin N, Heimall J, Klein OR, Gennery AR, Slatter MA, Vickers MA, Orange JS, Heslop HE, Bollard CM, Keller MD.

J Allergy Clin Immunol. 2016 May;137(5):1498-1505.e1. doi: 10.1016/j.jaci.2015.12.1311. Epub 2016 Feb 24.

39.

Quantitative activation suppression assay to evaluate human bone marrow-derived mesenchymal stromal cell potency.

Salem B, Miner S, Hensel NF, Battiwalla M, Keyvanfar K, Stroncek DF, Gee AP, Hanley PJ, Bollard CM, Ito S, Barrett AJ.

Cytotherapy. 2015 Dec;17(12):1675-86. doi: 10.1016/j.jcyt.2015.08.008. Epub 2015 Sep 28.

40.

CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.

Hanley PJ, Melenhorst JJ, Nikiforow S, Scheinberg P, Blaney JW, Demmler-Harrison G, Cruz CR, Lam S, Krance RA, Leung KS, Martinez CA, Liu H, Douek DC, Heslop HE, Rooney CM, Shpall EJ, Barrett AJ, Rodgers JR, Bollard CM.

Sci Transl Med. 2015 Apr 29;7(285):285ra63. doi: 10.1126/scitranslmed.aaa2546. Erratum in: Sci Transl Med. 2016 Jan 13;8(321):321er1.

41.

A single bout of dynamic exercise enhances the expansion of MAGE-A4 and PRAME-specific cytotoxic T-cells from healthy adults.

LaVoy EC, Bollard CM, Hanley PJ, Blaney JW, O'Connor DP, Bosch JA, Simpson RJ.

Exerc Immunol Rev. 2015;21:144-53.

42.

A single bout of dynamic exercise by healthy adults enhances the generation of monocyte-derived-dendritic cells.

LaVoy EC, Bollard CM, Hanley PJ, O'Connor DP, Lowder TW, Bosch JA, Simpson RJ.

Cell Immunol. 2015 May;295(1):52-9. doi: 10.1016/j.cellimm.2015.02.007. Epub 2015 Feb 25.

PMID:
25749006
43.

Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood.

Hanley PJ, Bollard CM, Brunstein CG.

Cytotherapy. 2015 Jun;17(6):749-755. doi: 10.1016/j.jcyt.2014.12.007. Epub 2015 Jan 24. Review.

44.

Therapeutic mesenchymal stromal cells: where we are headed.

Hanley PJ.

Methods Mol Biol. 2015;1283:1-11. doi: 10.1007/7651_2014_175.

PMID:
25537839
45.

Using the quantum cell expansion system for the automated expansion of clinical-grade bone marrow-derived human mesenchymal stromal cells.

Martin-Manso G, Hanley PJ.

Methods Mol Biol. 2015;1283:53-63. doi: 10.1007/7651_2014_164.

PMID:
25523809
46.

Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.

Melenhorst JJ, Castillo P, Hanley PJ, Keller MD, Krance RA, Margolin J, Leen AM, Heslop HE, Barrett AJ, Rooney CM, Bollard CM.

Mol Ther. 2015 Jan;23(1):179-83. doi: 10.1038/mt.2014.192. Epub 2014 Sep 30.

47.

Mouse macrophages completely lacking Rho subfamily GTPases (RhoA, RhoB, and RhoC) have severe lamellipodial retraction defects, but robust chemotactic navigation and altered motility.

Königs V, Jennings R, Vogl T, Horsthemke M, Bachg AC, Xu Y, Grobe K, Brakebusch C, Schwab A, Bähler M, Knaus UG, Hanley PJ.

J Biol Chem. 2014 Oct 31;289(44):30772-84. doi: 10.1074/jbc.M114.563270. Epub 2014 Sep 11.

48.

Controlling cytomegalovirus: helping the immune system take the lead.

Hanley PJ, Bollard CM.

Viruses. 2014 May 27;6(6):2242-58. doi: 10.3390/v6062242. Review.

49.

Finessing the manufacture of mesenchymal stromal cells.

Hanley PJ.

Cytotherapy. 2014 Jun;16(6):711-2. doi: 10.1016/j.jcyt.2014.04.001. No abstract available.

PMID:
24801376
50.

Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System.

Hanley PJ, Mei Z, Durett AG, Cabreira-Hansen Mda G, Klis M, Li W, Zhao Y, Yang B, Parsha K, Mir O, Vahidy F, Bloom D, Rice RB, Hematti P, Savitz SI, Gee AP.

Cytotherapy. 2014 Aug;16(8):1048-58. doi: 10.1016/j.jcyt.2014.01.417. Epub 2014 Apr 13. Erratum in: Cytotherapy. 2014 Oct;16(10):1449. Cabreira-Harrison, Marie da Graca [corrected to Cabreira-Hansen, Maria da Graca].

Supplemental Content

Loading ...
Support Center